ROTHBLATT MARTINE A sold $5.1M of UTHR (indirect holdings)
ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $531.74 ($528.72–$535.03, $5.05M total) across 7 trades on 2026-07-24 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed open-market sale totaling $5.05M could slightly pressure sentiment, but the 10b5-1 plan suggests the trades were scheduled in advance.
Market read
Traders may monitor for follow-on insider activity, but this specific disclosure is unlikely to drive a major repricing absent other catalysts.
What to watch
The filing notes indirect holdings and multiple small trades; without context on total compensation, taxes, or prior sale cadence, the signal strength is limited.
Background
The article is an SEC Form 4 insider transaction disclosure for United Therapeutics, reported by its Chairperson and CEO.
Ticker impact
Form 4 shows UTHR CEO sold 9,500 shares in an open-market transaction totaling about $5.05M, under a 10b5-1 plan.
Likely limited, short-lived sentiment impact; follow-through depends on broader fundamentals and any concurrent news.
The filing is a primary-source insider transaction with a stated 10b5-1 pre-arranged plan, which typically dampens inference about new negative information.
Market effects
Minimal sector read-through; this is company-specific insider activity without disclosed operational or regulatory changes.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect routine liquidity needs rather than a change in outlook.
Key entities
- issuerUNITED THERAPEUTICS Corp
Company whose CEO reported an open-market insider sale on Form 4.
- insiderROTHBLATT MARTINE A
Chairperson and CEO who reported the sale of shares, with indirect holdings and a 10b5-1 plan.
